权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Exploration of the innovation patterns in emerging, highly convergent life sciences domains

探索新兴、高度融合的生命科学领域的创新模式

基本信息

批准号：
16K17165
负责人：
Avila Alfonso
金额：
$ 2万
依托单位：
Kyoto University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Young Scientists (B)
财政年份：
2016
资助国家：
日本
起止时间：
2016-04-01 至 2018-03-31
项目状态：
已结题

项目摘要

In FY2017, I completed the global mapping of convergent scientific research, which included the processing of 1.5 million publications and 24,000 clusters across all fields of science. Building on this map, I selected three cases of highly convergent life science domains to examine their patterns of innovation: (a) the study of the factors influencing the evolution of emerging iPS cell-based therapies, (b) the examination of the evolution and patterns of collaboration in next-generation cancer immunotherapies, and (c) the assessment of convergence in Japan's WPI research centers. For these cases, we used a mixed-methods approach that includes scientific, technological and clinical data. Different domestic and international collaborations were built to conduct this research. Main outputs of this research are two manuscripts that are currently under review and will be added to this grant once they are accepted.A career change to a Kyoto University biotech spin-off in FY2017 impeded me to continue with my Kakenhi funding. However, my current affiliation at Kyoto University as an external research fellow will allow me to finalize the research plans of this project and to continue with the preparation of two additional manuscripts to be published in international journal publications. Owing to these changes, I was not able to attend international conferences, as planned.

在2017财年，我完成了融合科学研究的全球制图，其中包括处理所有科学领域的150万份出版物和24,000个集群。在这张地图的基础上，我选择了三个高度趋同的生命科学领域的案例来研究它们的创新模式：(a)研究影响新兴iPS细胞疗法发展的因素，(b)研究下一代癌症免疫疗法的发展和合作模式，以及(c)评估日本WPI研究中心的趋同情况。对于这些病例，我们使用了混合方法，包括科学，技术和临床数据。为了进行这项研究，建立了不同的国内和国际合作关系。这项研究的主要产出是两份手稿，目前正在审查中，一旦被接受，将加入本资助。2017财年，我转行到京都大学（Kyoto University）的一家生物技术分拆公司，这阻碍了我继续获得Kakenhi资助。然而，我目前作为京都大学的外部研究员，将允许我完成这个项目的研究计划，并继续准备另外两份将在国际期刊出版物上发表的手稿。由于这些变化，我不能按计划参加国际会议。